Abstract
Sulbactam is a betalactamase inhibitor which in combination with Ampicillin expands the spectrum of the latter to include Ampicillin resistant germs. To document the efficacy and safety of Sulbactam/Ampicillin a clinical study was performed in 25 children suffering from pneumonia. The dosage of Sulbactam/Ampicillin was 50 mg Sulbactam/100 mg Ampicillin per kg per day administered in three divided doses. Clinical cure was achieved in 22 children and failure of treatment was observed in 3 children. Side effects occured in 2 patients in form of transient exanthema which did not necessitate termination of treatment. Slight and transient elevation of transaminases was observed in 4 children and transient eosinophilia occured in 2 patients. The results confirmed that Sulbactam/Ampicillin is an effective and well-tolareted treatment in children with pneumonia.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scholz, H. SULBACTAM/AMPICILLIN IN CHILDREN WITH BACTERIAL PNEUMONIA. Pediatr Res 19, 1107 (1985). https://doi.org/10.1203/00006450-198510000-00225
Issue Date:
DOI: https://doi.org/10.1203/00006450-198510000-00225